Drug Trial Radar · NCT00315341
Starting Treatment With Agonist Replacement Therapies (START)
Last checked: Nov 19, 2026Latest source record: Jan 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,269
Actual
Start
Apr 2006
Primary completion
Aug 2010
Study completion Aug 2010
Sponsor
- Lead sponsor
- University of California, Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Apr 18, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Food and Drug Administration (FDA) has requested a study comparing buprenorphine/naloxone (BUP/NX) and methadone (MET) on indices of hepatic safety.
Conditions
- Opiate-related Disorders
Interventions
Buprenorphine/naloxoneDrug
Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
MethadoneDrug
Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hepatic SafetyTime frame: 24 Weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Matrix Institute
Los Angeles, California
Bi-Valley Medical Clinic INC.
Sacramento, California
BAART; Turk Street Clinic
San Francisco, California
Hartford Dispensary
Hartford, Connecticut
CT Counseling Centers
Waterbury, Connecticut
Addiction Research & Treatment Corp
Brooklyn, New York
CODA-Research
Portland, Oregon
NET Steps
Philadelphia, Pennsylvania
Evergreen Treatment Services
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.